All news from Physiology

Fetus Increases Risk Of Reproductive Aging

Being malnourished in utero makes it more likely to be a woman will experience early menopause and premature ovarian failure (POF) relative to women not malnourished during fetal development, according to a study of a large sample of Chinese women who lived through the Great Famine.

18F-FDG Cardiac PET Inflammation With Breast Cancer Radiotherapy

Radiotherapy for the treatment of left-sided breast cancer increases the long term risk of cardiovascular disease. The purpose of this study was to non-invasively image the progression of radiation-induced cardiac inflammation in a large animal model using a hybrid positron emission tomography and magnetic resonance imaging system.

Overdoing And Over prescribing Antibiotics

Antibiotics are life-savers. But they're being overprescribed and overused, leading to antibiotic-resistant germs stronger than the drugs available to treat them. This is also creating more drug side effects, allergic reactions and serious infections.

Optimal Treatment Of Pediatric Wrist Fracture

There is too little evidence to recommend any one approach to treating wrist fractures in children, the authors of a new Cochrane review conclude. However, there is reassuring evidence of a full return to previous function with no serious adverse events

Pulmonary Embolism: IVC Filters May Increase Mortality Risk

Use of inferior vena cava (IVC) does not appear to have a mortality benefit – and may confer to mortality risk – in older adults with  pulmonary embolism (PE), a study has shown. 

The results of the study, conducted by Behnood Bikdeli and colleagues, were  published online  in a research letter in  JAMA Internal Medicine . The findings contradict those from previous analyses of administrative databases in which there was limited adjustment for potential confounders, they write

Research: Phase III KATHERINE Trial Crossed Early Reporting Boundary

Substituting trastuzumab emtansine (T-DM1, Kadcyla) for adjuvant trastuzumab (Herceptin) in patients who had residual disease after receiving neoadjuvant chemotherapy and trastuzumab reduced the risk of developing an invasive recurrence of HER2-positive early-stage breast cancer by 50%, according to data from the phase III clinical trial KATHERINE presented at the 2018 San Antonio Breast Cancer Symposium, held Dec. 4-8.